Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
Galadanci NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, Aminu H, Tijjani A, Abba MS, Tabari MA, Galadanci A, Borodo AM, Belonwu R, Salihu AS, Rodeghier M, Ghafuri DL, Covert C Greene BV, Neville K, Kassim AA, Kirkham FJ, Jordan LC, Aliyu MH, DeBaun MR.
Galadanci NA, et al. Among authors: salihu as.
Am J Hematol. 2020 Sep;95(9):E247-E250. doi: 10.1002/ajh.25900. Epub 2020 Jul 10.
Am J Hematol. 2020.
PMID: 32510680
Free PMC article.
Clinical Trial.
No abstract available.